Table 4.
Race | No. of participants in the intervention group whose disease recurred | No. of participants in the comparison group whose disease recurred | Breast cancer events, HR (95% CI) | P value | No. of deaths in the intervention group | No. of deaths in the comparison group | Mortality, HR (95% CI) | P value |
---|---|---|---|---|---|---|---|---|
Asian* | 6/46 | 3/50 | 2.09 (0.52 – 8.49) | 0.300 | 4/46 | 4/50 | 0.85 (0.20 – 3.50) | 0.819 |
African-American* | 14/61 | 8/57 | 1.61 (0.67 – 3.87) | 0.288 | 10/61 | 6/57 | 1.45 (0.52 – 4.03) | 0.477 |
Hispanic† | 13/87 | 16/78 | 0.67 (0.31 – 1.43) | 0.362 | 8/87 | 10/78 | 0.70 (0.26 – 1.87) | 0.479 |
white‡ | 216/1306 | 223/1328 | 0.98 (0.82 – 1.19) | 0.864 | 127/1306 | 133/1328 | 0.98 (0.77 – 1.30) | 0.868 |
Note: Adjustments were made based on baseline differences between intervention and comparison conditions.
HR = hazard ratio; CI = confidence interval.
Survivors were followed for a mean of 7.3 years
Models were adjusted for baseline body mass index.
Models were adjusted for age at study entry, age at diagnosis, radiation treatment and menopausal status.
Models were adjusted for anti-estrogen use.